Cargando…

Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery

OBJECTIVE: The objective of this clinical trial is to study the effectiveness of administering recombinant activated factor VII (rFVIIa) in reducing the amount of bleeding and the need for homologous blood and products transfusion in cardiac surgical coronary revascularization procedures done under...

Descripción completa

Detalles Bibliográficos
Autor principal: Abdel-Meguid, Mohamed Essam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757804/
https://www.ncbi.nlm.nih.gov/pubmed/24015134
http://dx.doi.org/10.4103/1658-354X.115364
_version_ 1782282271720472576
author Abdel-Meguid, Mohamed Essam
author_facet Abdel-Meguid, Mohamed Essam
author_sort Abdel-Meguid, Mohamed Essam
collection PubMed
description OBJECTIVE: The objective of this clinical trial is to study the effectiveness of administering recombinant activated factor VII (rFVIIa) in reducing the amount of bleeding and the need for homologous blood and products transfusion in cardiac surgical coronary revascularization procedures done under cardiopulmonary bypass (CPB). METHODS: In a randomized controlled prospective observational study, 30 patients were scheduled for elective cardiac revascularization under CPB. Patients were randomly allocated into two groups. In Group I (Control group), no rFVIIa was administered following CPB. In Group II (Study group), a dose of 90 ug/Kg of rFVIIa was administered following weaning off CPB. The total amount of chest tube drain during the 1(st) 24 h following surgery was recorded as well as the qualitative and quantitative assessments of homologous blood and products transfusion. Serial analysis of hematological parameters including hemoglobin level and coagulation test in a definite data points was done. T0=baseline readings prior to CPB, T1=off CPB after protamine administration and before administration of the study drug, T2=on Cardiac Intensive Care Unit (CICU) admission, T3=12 h post-CICU admission, and T4=24 h post-CICU admission. RESULTS: Considering the total chest tube drainage, mean values showed statistically significant results with a P value of 0.001. Homologous blood and products transfusion were statistically lower in the study group. Regarding the mean values for hematological assessment, results showed statistically lower International Normalized Ratio values at CICU admission and 12 h post-CICU admission with a P value of 0.018 and 0.004, respectively. Also, the Partial Thromboplastin Time mean values were statistically lower at same timings with estimated P values of 0.04 and 0.001, respectively. CONCLUSION: It is concluded that the prophylactic use of rFVIIa in patients undergoing coronary revascularization surgery under the management of CPB had a remarkable significant results on both the amount of post-operative bleeding and the amount of blood and products transfusion.
format Online
Article
Text
id pubmed-3757804
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37578042013-09-06 Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery Abdel-Meguid, Mohamed Essam Saudi J Anaesth Original Article OBJECTIVE: The objective of this clinical trial is to study the effectiveness of administering recombinant activated factor VII (rFVIIa) in reducing the amount of bleeding and the need for homologous blood and products transfusion in cardiac surgical coronary revascularization procedures done under cardiopulmonary bypass (CPB). METHODS: In a randomized controlled prospective observational study, 30 patients were scheduled for elective cardiac revascularization under CPB. Patients were randomly allocated into two groups. In Group I (Control group), no rFVIIa was administered following CPB. In Group II (Study group), a dose of 90 ug/Kg of rFVIIa was administered following weaning off CPB. The total amount of chest tube drain during the 1(st) 24 h following surgery was recorded as well as the qualitative and quantitative assessments of homologous blood and products transfusion. Serial analysis of hematological parameters including hemoglobin level and coagulation test in a definite data points was done. T0=baseline readings prior to CPB, T1=off CPB after protamine administration and before administration of the study drug, T2=on Cardiac Intensive Care Unit (CICU) admission, T3=12 h post-CICU admission, and T4=24 h post-CICU admission. RESULTS: Considering the total chest tube drainage, mean values showed statistically significant results with a P value of 0.001. Homologous blood and products transfusion were statistically lower in the study group. Regarding the mean values for hematological assessment, results showed statistically lower International Normalized Ratio values at CICU admission and 12 h post-CICU admission with a P value of 0.018 and 0.004, respectively. Also, the Partial Thromboplastin Time mean values were statistically lower at same timings with estimated P values of 0.04 and 0.001, respectively. CONCLUSION: It is concluded that the prophylactic use of rFVIIa in patients undergoing coronary revascularization surgery under the management of CPB had a remarkable significant results on both the amount of post-operative bleeding and the amount of blood and products transfusion. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3757804/ /pubmed/24015134 http://dx.doi.org/10.4103/1658-354X.115364 Text en Copyright: © Saudi Journal of Anaesthesia http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Abdel-Meguid, Mohamed Essam
Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery
title Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery
title_full Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery
title_fullStr Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery
title_full_unstemmed Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery
title_short Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery
title_sort prophylactic administration of recombinant activated factor vii in coronary revascularization surgery
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757804/
https://www.ncbi.nlm.nih.gov/pubmed/24015134
http://dx.doi.org/10.4103/1658-354X.115364
work_keys_str_mv AT abdelmeguidmohamedessam prophylacticadministrationofrecombinantactivatedfactorviiincoronaryrevascularizationsurgery